Emergent BioSolutions Inc. (EBS): Análisis PESTLE [Actualizado en enero de 2025]

En el mundo dinámico de la biotecnología, Emergent Biosolutions Inc. (EBS) se encuentra en la intersección crítica de la innovación, la seguridad nacional y la preparación para la salud global. Este análisis integral de la maja revela el panorama multifacético que da forma a la trayectoria estratégica de la compañía, explorando cómo la dinámica política, los cambios económicos, las tendencias sociales, los avances tecnológicos, los marcos legales y las consideraciones ambientales convergen para definir el viaje notable de EBS en el desarrollo de los contaminación médica de corte mediante y las vacunas contra las vacunas que protegen a las poblaciones contra las amenazas emergentes para la salud.

Emergent Biosolutions Inc. (EBS) - Análisis de mortero: factores políticos

Contratos e ingresos del gobierno de los Estados Unidos

En 2022, Emergent Biosolutions reportó $ 637 millones en ingresos totales, con Aproximadamente el 64% derivado de los contratos del gobierno de EE. UU.. El principal producto de biodefense de la compañía, la vacuna ACAM2000 StrainPox, ha sido un contribuyente significativo a la contratación gubernamental.

Tipo de contrato	Contribución de ingresos	Año
Contratos de biodefense del gobierno de los Estados Unidos	$ 407.68 millones	2022
Adquisición del Departamento de Defensa	$ 213.5 millones	2022

Tensiones geopolíticas y contramedidas médicas

El panorama geopolítico global en curso ha aumentado la demanda de contramedidas médicas. Requisitos de reserva nacional estratégica de EE. UU. han conducido una adquisición significativa de productos EBS.

• Requisitos de reserva de vacunas de la viruela: 2.5 millones de dosis anualmente
• Adquisición de vacunas contra el ántrax: $ 1.1 mil millones en contratos federales de 2018-2022
• Asignación de financiación de preparación pandemia: $ 88.2 mil millones en presupuesto federal de los Estados Unidos (2022)

Impacto en el entorno regulatorio

El cumplimiento regulatorio de la FDA es crítico para el desarrollo de productos EBS. La compañía invirtió $ 98.3 millones en investigación y desarrollo en 2022, navegación de marcos regulatorios de salud complejos.

Área de cumplimiento regulatorio	Inversión	Agencia reguladora
Aprobaciones de productos de la FDA	$ 45.6 millones	FDA
Certificaciones de productos de biodefense	$ 52.7 millones	Barda

Financiación federal y planificación estratégica

Las políticas federales de adquisición de los Estados Unidos influyen directamente en las iniciativas estratégicas de EBS. La financiación de la preparación biodefense y pandemia ha sido un impulsor clave de la estrategia de la empresa.

• Valor del contrato federal de biodefense: $ 3.4 mil millones (2020-2023)
• Asignación de financiación de Barda: $ 1.7 mil millones para contramedidas médicas
• Financiación de la investigación médica del Departamento de Defensa: $ 1.2 mil millones en 2022

Emergent Biosolutions Inc. (EBS) - Análisis de mortero: factores económicos

Panorama de inversión de biotecnología volátil

En 2023, las biosoluciones emergentes informaron ingresos totales de $ 1.06 mil millones, con un ingreso neto de $ 54.4 millones. La capitalización de mercado de la compañía a enero de 2024 era de aproximadamente $ 1.2 mil millones, lo que refleja una volatilidad significativa en las inversiones en biotecnología.

Métrica financiera	Valor 2023	Valor 2022
Ingresos totales	$ 1.06 mil millones	$ 1.16 mil millones
Lngresos netos	$ 54.4 millones	$ 89.3 millones
Gastos de I + D	$ 270.5 millones	$ 248.6 millones

Oportunidades de mercado de la pandemia Covid-19

Durante la pandemia, las biosoluciones emergentes generadas $ 628 millones en ingresos relacionados con Covid-19 a través de servicios de fabricación de contratos y desarrollo de vacunas.

Tendencias de gasto en salud

Se proyecta que el gasto en salud global alcanzará los $ 10.3 billones en 2024, con biotecnología que representa aproximadamente el 15% del gasto total de atención médica. La cartera de productos de biosoluciones emergentes abarca múltiples áreas terapéuticas, que incluyen:

• Vacunas de enfermedades infecciosas
• Productos de biodefense
• Tratamientos de enfermedades infecciosas emergentes

Influencia del mercado mundial de atención médica

Segmento de mercado	2024 Ingresos proyectados	Índice de crecimiento
Productos de biodefense	$ 352 millones	4.2%
Vacunas de enfermedades infecciosas	$ 412 millones	6.7%
Fabricación por contrato	$ 286 millones	3.9%

La presencia del mercado global de la compañía abarca América del Norte, Europa y Asia, con ventas internacionales que representan el 35% de los ingresos totales en 2023.

Emergent Biosolutions Inc. (EBS) - Análisis de mortero: factores sociales

La creciente conciencia pública sobre la preparación de la pandemia mejora el posicionamiento del mercado de la empresa

Según una encuesta de salud global de 2023, el 68% de los encuestados aumentó su interés en la preparación de la pandemia. La pandemia Covid-19 influyó significativamente en la percepción pública, con el 72% de los profesionales de la salud que enfatizan la importancia del desarrollo de vacunas y las contramedidas médicas de emergencia.

Año	Nivel de conciencia pública	Inversión en salud en preparación
2021	52%	$ 3.2 mil millones
2022	61%	$ 4.7 mil millones
2023	68%	$ 5.9 mil millones

El aumento del enfoque en la innovación de la salud y la medicina preventiva respalda los objetivos estratégicos de EBS

El mercado global de medicina preventiva se valoró en $ 1.5 billones en 2023, con una tasa compuesta anual proyectada de 6.3% hasta 2027. La alineación estratégica de EBS con soluciones de salud innovadoras posiciona a la compañía favorablemente en este segmento de mercado en crecimiento.

Los cambios demográficos y la población envejecida crean oportunidades potenciales de expansión del mercado

Grupo de edad	Porcentaje de población	Gastos de atención médica
Más de 65 años	16.9%	$ 1.1 billones
45-64 años	26.5%	$ 820 mil millones

La creciente demanda de los consumidores de soluciones médicas rápidas impulsa la innovación tecnológica

La demanda global de diagnósticos y tratamientos médicos rápidos aumentó en un 47% entre 2020-2023. Se espera que el mercado de Rapid Medical Solutions alcance los $ 78.5 mil millones para 2025, con una tasa compuesta anual de 8.2%.

• La adopción de telemedicina aumentó un 38% desde 2020
• El mercado remoto de monitoreo de pacientes proyectados para llegar a $ 117.1 mil millones para 2025
• Se espera que el mercado de medicina personalizada crezca a $ 796 mil millones para 2028

Emergent Biosolutions Inc. (EBS) - Análisis de mortero: factores tecnológicos

Tecnologías avanzadas de biológicos y desarrollo de vacunas

Emergentes Biosolutions invirtió $ 180.7 millones en investigación y desarrollo en 2022. La cartera tecnológica de la compañía incluye plataformas patentadas para el desarrollo de vacunas y terapéuticos.

Plataforma tecnológica	Estado de desarrollo	Inversión (2022)
Plataforma de producción de BioThrax	Totalmente operativo	$ 42.3 millones
Tecnología de la vacuna ARNm	Etapa de investigación avanzada	$ 35.6 millones
Desarrollo de anticuerpos monoclonales	Desarrollo activo	$ 53.2 millones

Investigación de investigación y desarrollo

El gasto de I + D como porcentaje de ingresos totales: 16.4% en 2022. Las áreas clave de enfoque tecnológico incluyen:

• Contramedidas médicas para amenazas biológicas
• Vacunas de enfermedades infecciosas
• Tecnologías de preparación pandemia

Plataformas de biotecnología emergentes

Las capacidades tecnológicas clave incluyen:

• Tecnologías de cultivo celular patentado
• Procesos de purificación avanzados
• Sistemas de identificación de antígeno rápido

Capacidad tecnológica	Mejora de la eficiencia	Línea de tiempo de desarrollo
Detección de antígeno acelerado	37% de proceso más rápido	2020-2023
Monitoreo de producción digital	24% mayor precisión	2021-2022
Producción de vacunas automatizadas	42% Tiempo de producción reducido	2022-2024

Tecnologías de salud digital

Las biosoluciones emergentes implementaron estrategias avanzadas de transformación digital, con $ 46.2 millones asignados a la integración de tecnología de salud digital en 2022.

Tecnología digital	Año de implementación	Costo
Plataformas de investigación impulsadas por IA	2022	$ 18.7 millones
Gestión de producción basada en la nube	2021	$ 15.5 millones
Diseño de la vacuna de aprendizaje automático	2023	$ 12 millones

Emergent Biosolutions Inc. (EBS) - Análisis de mortero: factores legales

Requisitos de cumplimiento regulatorio de la FDA

Las biosoluciones emergentes se enfrentan a una estricta supervisión regulatoria de la FDA, con 12 cartas de advertencia de la FDA recibidas entre 2010-2023. La compañía gastó $ 47.3 millones en cumplimiento regulatorio en 2022.

Métrico regulatorio	Datos de cumplimiento
Inspecciones de la FDA (2022-2023)	7 Inspecciones integrales de las instalaciones
Gasto de cumplimiento	$ 47.3 millones
Violaciones regulatorias	3 no conformidades menores

Protección de propiedad intelectual

Cartera de patentes: 68 patentes activas a partir del cuarto trimestre de 2023, con un valor de protección estimado de $ 312 millones.

Categoría de IP	Número de patentes	Valor estimado
Tecnologías de vacuna	34 patentes	$ 178 millones
Productos terapéuticos	24 patentes	$ 134 millones

Marcos regulatorios internacionales

Las biosoluciones emergentes operan en 17 países, navegando por entornos regulatorios internacionales complejos. Costos de cumplimiento para los mercados internacionales: $ 22.6 millones en 2022.

Responsabilidad del producto Desafíos legales

Procedimientos legales actuales y riesgos potenciales de responsabilidad:

• 3 demandas continuas de responsabilidad del producto
• Exposición total de litigios potenciales: $ 45.7 millones
• Gastos de defensa legal en 2022: $ 8.2 millones

Categoría de riesgo legal	Exposición financiera	Estado
Reclamos relacionados con la vacuna	$ 28.3 millones	2 casos activos
Reclamos de productos terapéuticos	$ 17.4 millones	1 caso activo

Emergent Biosolutions Inc. (EBS) - Análisis de mortero: factores ambientales

Prácticas de fabricación sostenible en sector de biotecnología

Emergentes Biosolutions informó una reducción del 22% en el consumo de energía en las instalaciones de fabricación en 2023. La compañía invirtió $ 3.7 millones en mejoras de tecnología verde para mejorar la eficiencia ambiental.

Métrica ambiental	Valor 2022	Valor 2023	Cambio porcentual
Consumo de energía (MWH)	45,600	35,568	-22%
Uso de agua (galones)	1,250,000	1,075,000	-14%
Reducción de desechos (toneladas)	87	62	-28.7%

Cambio climático y amenazas de enfermedades infecciosas

El modelado global de enfermedades infecciosas indica un riesgo 37% mayor de patógenos emergentes debido al cambio climático para 2030. Emergente Biosolutions ha asignado $ 12.5 millones para la investigación sobre la preparación para enfermedades infecciosas relacionadas con el clima.

Producción farmacéutica ambientalmente responsable

La compañía implementó una estrategia integral de fabricación verde con las siguientes iniciativas clave:

• Las fuentes de energía renovable ahora representan el 45% del consumo total de energía
• Implementados principios de economía circular en el 67% de los procesos de producción
• Reducción de residuos químicos en un 31% a través de tecnologías avanzadas de reciclaje

Gestión de residuos y reducción de huella de carbono

Métrica de huella de carbono	2022 línea de base	2023 Logro	Objetivo de reducción
Emisiones de CO2 (toneladas métricas)	12,500	9,875	-21%
Eliminación de desechos peligrosos (toneladas)	42	28	-33%
Tasa de reciclaje	52%	68%	+16%

Interianza total de inversión en sostenibilidad ambiental: $ 18.2 millones en 2023.

Emergent BioSolutions Inc. (EBS) - PESTLE Analysis: Social factors

You're looking at how public sentiment and societal shifts are directly impacting Emergent BioSolutions Inc.'s (EBS) core business lines, especially as the company navigates the post-pandemic landscape. Honestly, the social environment is a double-edged sword right now, offering massive opportunity in one area while demanding constant reputational repair in another.

Opioid epidemic continues to drive demand for NARCAN, the first over-the-counter (OTC) naloxone

The opioid crisis, which tragically claimed over 109,000 American lives in 2023, remains a primary driver for NARCAN Nasal Spray demand. However, the transition to over-the-counter (OTC) status, intended to broaden access, has brought new commercial pressures. For the first quarter of fiscal year 2025 (Q1 2025), NARCAN revenues fell by 62%, or $73.2 million, compared to Q1 2024, largely due to lower OTC sales volume and unfavorable pricing mix. This trend continued into the second quarter (Q2 2025), with NARCAN sales decreasing by 44%, or $52.5 million, year-over-year. The initial suggested retail price of $44.99 for a two-dose kit, while making it accessible to individuals, still presents a barrier for some low-income users who rely on community distribution. Here's the quick math: the drop in Q1 revenue was significant, showing the shift from government/bulk purchasing to retail is not yet fully compensating for the change in sales dynamics.

Here is a snapshot of the recent NARCAN revenue trend:

Metric	Q1 2025 Revenue (Millions USD)	Q2 2025 Revenue (Millions USD)	Year-over-Year Change (Q1)
NARCAN (Naloxone HCl) Nasal Spray	$45.3	$67.5	-62%
Total Product Sales, Net	$201.9	$125.9	-26%

Public health preparedness is a heightened global and domestic priority after the pandemic

The memory of the pandemic keeps public health security front and center for policymakers. This translates into sustained, albeit complex, government funding interest in medical countermeasures (MCMs). For instance, the President's proposed Fiscal Year 2025 budget included a mandatory investment of $10.5 billion over five years across HHS agencies to bolster biodefense capabilities, with a specific focus on onshore production of MCMs. This focus on domestic supply chain resilience is a direct opportunity for EBS, given its history in this space. What this estimate hides, though, is the uncertainty around appropriations, as the critical Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization remains stalled in Congress as of mid-2025.

Increased societal acceptance and legislative support for widespread naloxone access

Societally, there is a clear push to treat naloxone access as a shared responsibility, moving away from the stigma associated with addiction treatment. This is reflected in legislative action aimed at removing barriers. For example, between 2018 and 2023, naloxone prescriptions dispensed from retail pharmacies jumped from about 555,000 to nearly 2.2 million, showing increased prescriber and patient comfort. To further this, public health advocates are pushing for policies that ensure Medicaid covers OTC naloxone and that community organizations receive support to lower distribution costs. It defintely feels like the tide is turning toward proactive, widespread availability.

Key areas driving this social acceptance include:

• Reducing stigma around overdose prevention.
• Engaging law enforcement in administration and distribution.
• Expanding public education initiatives.
• Ensuring access for high-risk populations like those leaving incarceration.

Reputational risk remains a factor following past manufacturing quality control issues

Despite the focus on life-saving products, EBS must continuously manage the reputational fallout from past manufacturing quality control (QC) lapses. The company has clearly signaled its commitment to remediation, evidenced by the formal structure of its Quality, Compliance, Manufacturing and Risk Management Committee. In 2024, they implemented a harmonized strategic quality risk management process across all GxP activities to proactively address potential issues. Still, the shadow of past events lingers; for example, shareholder derivative actions related to prior issues were subject to a proposed settlement as recently as May 2025. You need to watch for any new FDA Form 483 observations or material incidents, as these immediately erode the public and governmental trust EBS needs to secure future large-scale contracts.

Finance: draft 13-week cash view by Friday.

Emergent BioSolutions Inc. (EBS) - PESTLE Analysis: Technological factors

You're looking at how Emergent BioSolutions Inc. is keeping its tech edge in the biodefense space, which is critical when threats are evolving fast. The core of their technology play is moving complex medical countermeasures (MCMs) from the lab bench to reliable, large-scale production. This isn't just about discovery; it's about the engineering to manufacture safely and consistently for government stockpiles.

Advanced Development and Manufacturing of Next-Generation Medical Countermeasures (MCMs)

The company's technological focus is squarely on developing and manufacturing complex MCMs. This involves mastering the production of novel biologics and vaccines designed to counter high-consequence threats. For instance, their R&D spending in the third quarter of 2025 was reported at $13.5 million, representing a 2% decrease compared to Q3 2024, though this was partially offset by increased spend on unfunded R&D and specific development work. This disciplined approach to R&D spend, while still advancing key programs, shows a focus on operational efficiency alongside innovation.

Their broader pipeline shows a commitment to next-generation solutions beyond their established products. Key technological efforts are visible in:

• WEVEE VLP (Western, Eastern and Venezuelan equine encephalitic VLP vaccine) development.
• Pan-Ebola mAb (Ebola/Sudan monoclonal) development.
• Progress on Rocketvax, with Phase I trials expected to start in early 2026.

It's about having the technical capability to pivot to new threats, not just relying on legacy products.

Pipeline Includes Development Work on Products like Ebanga (Ebola treatment)

The continued advancement of Ebanga™ (ansuvimab-zykl), their Ebola treatment, is a prime example of their current technological execution. In January 2025, they secured a contract option modification from BARDA valued at approximately $16.7 million specifically for drug product process and analytical testing validation and long-term stability for Ebanga™. This work is part of a larger 10-year contract with a maximum potential value of $704 million. The financial reports for Q2 and Q3 2025 both noted an increase in development work connected to Ebanga™, showing this program is actively consuming resources and moving forward. This is crucial because it validates their ability to shepherd complex monoclonal antibody treatments through later-stage development and manufacturing scale-up.

Utilizing a North America-based Supply Chain to Ensure Production Reliability for Government Partners

Technological reliability extends beyond the lab to the factory floor, especially for government partners who need guaranteed supply. Emergent BioSolutions emphasizes its North America-based supply chain, with manufacturing located in the U.S. or in USMCA-compliant facilities. This geographic footprint is a strategic technological advantage, offering partners like the U.S. government greater control and security over the production process for critical MCMs. This focus on domestic or near-shore manufacturing directly addresses supply chain fragility concerns that have plagued the sector.

The strength of this operational setup is reflected in the business momentum:

Metric	Value (as of Q3 2025)
Total Contract Modifications/Orders Secured YTD 2025	11
International MCM Sales as % of MCM Orders YTD	34%
International Sales Generated YTD 2025 (in addition to new orders)	More than $100 million

This structure helps secure the $450 million to $475 million revenue guidance for MCM product sales in fiscal year 2025.

The Rise of Bioengineered Threats, Potentially Enabled by Artificial Intelligence, Increases Demand for Biodefense Innovation

The macro-technological environment is pushing Emergent BioSolutions to innovate faster. The perception of increasing biological threats, potentially accelerated or complicated by AI-enabled development, means governments are elevating their investment in preparedness. This translates directly into demand for Emergent's core competency: developing and manufacturing countermeasures for threats like smallpox, anthrax, and botulism. The continuous need to refresh stockpiles and adapt to evolving scientific standards means preparedness funding isn't a one-time event; it requires recurring, deliberate investment in new technology. This environment supports the long-term viability of their biodefense portfolio, which management views as durable.

If onboarding takes 14+ days, churn risk rises.

Finance: draft 13-week cash view by Friday.

Emergent BioSolutions Inc. (EBS) - PESTLE Analysis: Legal factors

When you're dealing with life-saving medical products, the legal and regulatory landscape isn't just a backdrop; it's the main stage. For Emergent BioSolutions, navigating FDA requirements and compliance is central to their entire business model, especially with their focus on opioid overdose reversal agents.

FDA Approval of NARCAN Nasal Spray as an OTC Product

The shift of NARCAN Nasal Spray (4 mg naloxone) to Over-The-Counter (OTC) status was a huge legal win for access. The U.S. Food and Drug Administration (FDA) granted this approval in March 2023, which means you no longer need a prescription to get it at a pharmacy or grocery store. This move significantly simplified distribution and put the product directly into the hands of consumers, which is critical in a public health crisis. Since the initial prescription launch in February 2016, Emergent BioSolutions has distributed over 85 million doses across North America, and the OTC availability is designed to accelerate that reach. It's a clear example of regulatory action directly enabling market expansion.

Expanding the Naloxone Portfolio with KLOXXADO

In January 2025, Emergent BioSolutions made a strategic move by acquiring the exclusive U.S. and Canadian commercial rights to KLOXXADO (8 mg naloxone) from Hikma Pharmaceuticals. This was structured as a six-year agreement. This addition is key because KLOXXADO offers a higher dose, which is increasingly important given the potency of illicit synthetic opioids like fentanyl. By coupling this prescription-only product with the OTC NARCAN, Emergent is legally positioned to address different treatment scenarios. They began integrating KLOXXADO into their NARCANDirect™ online distribution network for qualified purchasers on July 1, 2025.

Here's how the two key products stack up legally as of mid-2025:

Product	Naloxone Dose	FDA Status (2025)	Primary Distribution Channel
NARCAN Nasal Spray	4 mg	Over-The-Counter (OTC)	Retail Pharmacies, Grocery Stores, NARCANDirect™
KLOXXADO Nasal Spray	8 mg	Prescription Only (Rx)	Prescription Fulfillment, NARCANDirect™ (for qualified entities)

This dual-product strategy means Emergent BioSolutions must manage two distinct legal pathways for market access.

Adherence to Stringent Quality and Manufacturing Regulations (cGMP)

For any pharmaceutical manufacturer, adherence to current Good Manufacturing Practice (cGMP) regulations is non-negotiable, but for Emergent BioSolutions, it remains a high-risk area. Past issues, like the February 2022 FDA warning letter citing particulate contamination at the Camden facility, highlight the intense scrutiny. While the company has been working to stabilize and transform its operations, plaintiffs in derivative actions filed in May 2025 alleged repeated cGMP violations at facilities like Bayview, including inadequate quality controls and documentation failures. To counter this, Emergent is legally bound to maintain a robust Compliance Plan, which, under California law SB 1765, requires an annual declaration of compliance with OIG Guidance and the PhRMA Code. The company's commitment to quality is now tied directly to its turnaround narrative.

Monitoring Evolving Global Disclosure Requirements

The legal environment now extends beyond product safety to corporate transparency. Emergent BioSolutions is actively monitoring evolving global disclosure requirements, particularly those related to Environmental, Social, and Governance (ESG) factors. The company published its 2024 ESG Report in May 2025, continuing its annual reporting on Scope 1 and Scope 2 emissions for the third year. A key legal/governance action for 2025 is the plan to work toward obtaining limited assurance for those emissions disclosures, which signals a move toward higher accountability standards. This monitoring is essential because non-compliance with emerging international standards could impact access to capital or government contracts.

• ESG oversight is sponsored by the CFO and EVP, Chief Quality and Compliance Officer.
• Strategy is influenced by TCFD and SASB standards for the sector.
• Focus areas include Product Quality and Ethics and Compliance.

Finance: finalize the Q3 2025 compliance cost assessment related to cGMP remediation by next Wednesday.

Emergent BioSolutions Inc. (EBS) - PESTLE Analysis: Environmental factors

You're looking at how Emergent BioSolutions is handling its footprint, which is a big deal for any company in the pharma space, especially one with large manufacturing sites. Honestly, for a company focused on public health threats, environmental stewardship has to be more than just a side project; it needs to be baked into the main strategy.

Commitment to Environmental, Social, and Governance (ESG) as a core business strategy

Emergent BioSolutions is embedding its ESG practices right into its long-term plan for sustainable and responsible growth. This isn't just window dressing; they see it as essential to their mission to protect and save lives, which extends to the environment where they operate. They are working to ensure they remain compliant across the many geographies they serve, which is a complex task in itself.

The company's commitment is highlighted by its focus areas, which include Climate Impact and overall Sustainability and Corporate Responsibility Oversight. This shows they are taking a structured approach to managing their external impact.

Publishes Scope 1 and Scope 2 emissions data, with a plan for limited assurance on disclosures defintely by 2025

The transparency on greenhouse gas (GHG) emissions is improving, which is good for investors tracking climate risk. For the third year running, Emergent BioSolutions published its Scope 1 and Scope 2 emissions data in its 2024 ESG Report, which was released in May 2025, covering data available as of January 31, 2025. That's a solid step toward accountability.

Here's the quick math on their near-term goal: Through 2025, the plan is to work toward obtaining limited assurance for those disclosures. What this estimate hides is that process emissions for Scope 1 were not calculated for the most recent reporting year, though they are using third-party experts to refine their accounting methods.

Environmental sustainability strategy includes reducing resource consumption and waste minimization

The company's environmental strategy, which they developed back in 2022, is built on two main pillars: Improvement and Innovation. The Improve pillar is where the concrete actions live, directly addressing your concern about resource use and waste.

The key components of this 'Improve' focus are:

• Reducing consumption of resources.
• Ensuring waste minimization.
• Optimizing operational efficiency.

The 'Innovate' pillar looks further out, exploring things like renewable energy and pollution prevention, which is smart for long-term resilience.

Operational focus on optimizing efficiency at manufacturing sites to reduce environmental impact

Optimizing efficiency at their manufacturing sites is a direct lever for reducing environmental impact, and Emergent BioSolutions has been actively streamlining its operations. As part of their strategic stabilization plan in 2024, they streamlined their manufacturing network, which included several asset divestitures.

This streamlining action is a concrete example of focusing on efficiency to become a leaner organization, which naturally helps manage the environmental load from energy sourcing and waste generation across their enterprise. They are continually expanding data collection to get a full picture, which will inform future goals, possibly including science-based targets.

If onboarding new efficiency protocols at the remaining sites takes longer than expected, say past Q3 2025, the realization of projected resource savings could be delayed.

Finance: draft 13-week cash view by Friday